Following Advisory Committee Success, Gilead Focused On Broad HCV Effort
This article was originally published in The Pink Sheet Daily
Anticipating near-term U.S. and EU approvals of sofosbuvir for hepatitis C, Gilead is looking ahead to expanding the nucleoside polymerase inhibitor’s label, including a two-drug combination pill regimen for genotype 2 patients in Japan. Meanwhile, HIV drugs Stribild and Complera posted significant sales growth during the third quarter.
You may also be interested in...
With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.
FDA’s Bumpus Will Be Principal Deputy Commissioner; Cosmetics Industry Reacts With Congratulations, Questions
Chief scientist Namandjé Bumpus will replace Janet Woodcock as principal deputy commissioner at the US FDA when the latter steps down in early 2024. The Personal Care Products Council says Bumpus will continue to lead MoCRA implementation efforts while a new chief scientist is sought, but those and other details remain fuzzy.
Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.